BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 38739112)

  • 1. Discovery of Novel Small-Molecule-Based Potential PD-L1/EGFR Dual Inhibitors with High Druggability for Glioblastoma Immunotherapy.
    Yang Z; Liu Z; Wan S; Xu J; Huang Y; He H; Liu T; Li L; Ren Y; Zhang J; Chen J
    J Med Chem; 2024 May; 67(10):7995-8019. PubMed ID: 38739112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Small and Bifunctional Molecules Targeting PD-L1/CD73 for Cancer Dual Immunotherapy.
    Wang S; Kong Z; Shi Y; Shao C; Wang W; Su Z; Liu J; Zhou Y; Fei X; Cheng B; Chen J; Lu Y; Xiao J
    J Med Chem; 2024 Jun; 67(11):9447-9464. PubMed ID: 38748913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction.
    Xu C; Sun Z; Zhang X; Zang Q; Yang Z; Li L; Yang X; He Y; Ma Z; Chen J
    Bioorg Chem; 2024 Jun; 147():107376. PubMed ID: 38640722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment.
    Cheng B; Wang W; Niu X; Ren Y; Liu T; Cao H; Wang S; Tu Y; Chen J; Liu S; Yang X; Chen J
    J Med Chem; 2020 Dec; 63(24):15946-15959. PubMed ID: 33264007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1.
    Cheng B; Ren Y; Cao H; Chen J
    Eur J Med Chem; 2020 Aug; 199():112377. PubMed ID: 32388281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.
    Chen R; Yuan D; Ma J
    Future Med Chem; 2022 Jan; 14(2):97-113. PubMed ID: 34870447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment.
    Yang X; Cheng B; Xiao Y; Xue M; Liu T; Cao H; Chen J
    Eur J Med Chem; 2021 Mar; 213():113058. PubMed ID: 33280898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel resorcinol biphenyl ether-based macrocyclic small molecules as PD-1/PD-L1 inhibitors with favorable pharmacokinetics for cancer immunotherapy.
    Yang Z; Liu Z; Xu C; Xu J; Liu T; He H; Li L; Ren Y; Chen J
    Bioorg Chem; 2023 Oct; 139():106740. PubMed ID: 37478546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular hybridization used to design and synthesize neo-tanshinlactone derivatives as PD-1/PD-L1 inhibitors.
    Zhang M; Liu J; Wang Y; Wang P; Morris-Natschke S; Lee KH
    Bioorg Med Chem; 2022 Jan; 54():116579. PubMed ID: 34954618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold.
    Chen H; Wang K; Yang Y; Huang X; Dai X; Feng Z
    Eur J Med Chem; 2021 May; 217():113377. PubMed ID: 33770574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving tumor sensitivity by the introduction of an ester chain to triaryl derivatives targeting PD-1/PD-L1.
    Zhang Y; Yin F; Luo Z; Li S; Li X; Wan S; Chen Y; Kong L; Wang X
    Eur J Med Chem; 2024 May; 271():116433. PubMed ID: 38678826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.
    Pan C; Yang H; Lu Y; Hu S; Wu Y; He Q; Dong X
    Eur J Med Chem; 2021 Mar; 213():113170. PubMed ID: 33454550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.
    Wang F; Ye W; Wang S; He Y; Zhong H; Wang Y; Zhu Y; Han J; Bing Z; Ji S; Liu H; Yao X
    Neoplasia; 2021 Mar; 23(3):281-293. PubMed ID: 33529880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
    Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
    Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents.
    Cheng B; Ren Y; Niu X; Wang W; Wang S; Tu Y; Liu S; Wang J; Yang D; Liao G; Chen J
    J Med Chem; 2020 Aug; 63(15):8338-8358. PubMed ID: 32667799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatment.
    Cao H; Cheng B; Liu T; Chen J
    Biochem Pharmacol; 2021 Jun; 188():114522. PubMed ID: 33741334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
    Yang Y; Wang K; Chen H; Feng Z
    Eur J Med Chem; 2021 Feb; 211():113001. PubMed ID: 33272783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
    Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
    Front Immunol; 2021; 12():637146. PubMed ID: 34025646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.